Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Gross Profit: 2023-2024

Historic Gross Profit for Entrada Therapeutics (TRDA) over the last 2 years, with Dec 2024 value amounting to $210.8 million.

  • Entrada Therapeutics' Gross Profit fell 91.75% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.5 million, marking a year-over-year decrease of 71.42%. This contributed to the annual value of $210.8 million for FY2024, which is 63.38% up from last year.
  • According to the latest figures from FY2024, Entrada Therapeutics' Gross Profit is $210.8 million, which was up 63.38% from $129.0 million recorded in FY2023.
  • Entrada Therapeutics' 5-year Gross Profit high stood at $210.8 million for FY2024, and its period low was $129.0 million during FY2023.
  • Over the past 2 years, Entrada Therapeutics' median Gross Profit value was $169.9 million (recorded in 2023), while the average stood at $169.9 million.
  • Data for Entrada Therapeutics' Gross Profit shows a peak YoY spiked of 63.38% (in 2024) over the last 5 years.
  • Entrada Therapeutics' Gross Profit (Yearly) stood at $129.0 million in 2023, then surged by 63.38% to $210.8 million in 2024.